Valganciclovir
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Valganciclovir is an oral prodrug of ganciclovir used to prevent and treat cytomegalovirus (CMV) disease, most often in solid-organ transplant recipients and in people with advanced HIV. After absorption it is rapidly converted to ganciclovir, which provides oral ganciclovir exposure comparable to intravenous dosing. Because of significant bone marrow and reproductive toxicity, it requires careful blood-count monitoring and dose adjustment for renal function.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Valganciclovir is an oral prodrug of ganciclovir used to prevent and treat cytomegalovirus (CMV) disease, most often in solid-organ transplant recipients and in people with advanced HIV. NutriStack rates the supporting evidence as strong. Common adult dosing is CMV retinitis induction: 900 mg twice daily with food for 21 days, then 900 mg once daily maintenance. Transplant prophylaxis: 900 mg once daily with food, started within 10 days of transplant and continued for ~100-200 days depending on organ and risk. All doses require reduction for reduced creatinine clearance., though a prescriber sets the actual dose. With long-term use it can deplete folate, magnesium. This profile indexes 3 sources.
The bottom line
Evidence rating strong. Most-documented uses: prevention of cmv disease in high-risk solid-organ transplant recipients (kidney, heart, kidney-pancreas), treatment of cmv retinitis in patients with aids, reduction of cmv viral load and end-organ disease. 3 sources indexed (2004–2017), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Valganciclovir is hydrolyzed by intestinal and hepatic esterases to ganciclovir, the active moiety. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine. In CMV-infected cells it is initially phosphorylated by the viral protein kinase encoded by the UL97 gene, then converted to ganciclovir triphosphate by host cellular kinases. Ganciclovir triphosphate competitively inhibits the viral DNA polymerase (UL54) and is incorporated into viral DNA, slowing and ultimately terminating viral DNA chain elongation. Because phosphorylation is far more efficient in virus-infected cells, the active drug is concentrated where the virus is replicating.1,3
Dosing & protocol.
Oral bioavailability of ganciclovir from valganciclovir is roughly 60 percent and increases when taken with food, so doses should be taken with meals. Tablets and oral solution are not interchangeable on a milligram-for-milligram basis at all doses.
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Folate
MildGanciclovir (the active moiety of valganciclovir) is a guanosine nucleoside analog that inhibits DNA synthesis and is markedly myelosuppressive, causing neutropenia, anemia, and thrombocytopenia. The resulting high turnover of bone marrow precursors increases demand on folate-dependent one-carbon metabolism for nucleotide synthesis, and functional folate status can become limiting during sustained marrow stress. This is a functional/relative depletion driven by hematopoietic demand rather than direct gut or renal loss.
Magnesium
MildGanciclovir/valganciclovir can cause renal tubular dysfunction and is frequently co-administered in transplant recipients receiving calcineurin inhibitors (cyclosporine, tacrolimus), which produce renal magnesium wasting. The antiviral contributes to nephrotoxicity and electrolyte disturbance, and clinically relevant hypomagnesemia is reported in this population, partly attributable to increased urinary magnesium loss.
Full safety detail.
Side effects
- Neutropenia and leukopenia
- Anemia
- Thrombocytopenia
- Diarrhea, nausea, and vomiting
- Headache
- Fever
- Tremor and other neurologic effects
- Elevated serum creatinine / impaired renal function
- Retinal detachment in patients with CMV retinitis
Contraindications
- Known hypersensitivity to valganciclovir, ganciclovir, or aciclovir/valaciclovir1,3
- Use with caution and dose-adjust in significant renal impairment3
- Severe pre-existing cytopenias (absolute neutrophil count typically below 500 cells/microliter or platelets below 25,000/microliter)
- Pregnancy and breastfeeding unless benefit clearly outweighs risk
- Not interchangeable with ganciclovir capsules on a one-to-one basis1,2
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1- 1Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipientsPaya C, Humar A, Dominguez E, et al. · American Journal of Transplantation · 2004
Once-daily valganciclovir was as effective as oral ganciclovir three times daily in preventing CMV disease in high-risk D+/R- transplant patients.
Reviews & position papers
1- 2Mechanism of action and resistance of ganciclovir against human cytomegalovirusBiron KK · Antiviral Research · 2006
Ganciclovir requires UL97-mediated initial phosphorylation; ganciclovir triphosphate inhibits the UL54 viral DNA polymerase and terminates viral DNA synthesis.
Reference material
1- 3Valcyte (valganciclovir) US Prescribing InformationGenentech USA, Inc. · FDA Prescribing Information · 2017
Approved for CMV retinitis in AIDS and for prevention of CMV disease in high-risk kidney, heart, and kidney-pancreas transplant recipients; standard dosing 900 mg with renal adjustment.
Common questions.
Quick answers about Valganciclovir, drawn from the data on this page.
What is Valganciclovir?
Valganciclovir is an oral prodrug of ganciclovir used to prevent and treat cytomegalovirus (CMV) disease, most often in solid-organ transplant recipients and in people with advanced HIV. After absorption it is rapidly converted to ganciclovir, which provides oral ganciclovir exposure comparable to intravenous dosing. Because of significant bone marrow and reproductive toxicity, it requires careful blood-count monitoring and dose adjustment for renal function.
What is Valganciclovir used for?
Commonly cited benefits of Valganciclovir include: Prevention of CMV disease in high-risk solid-organ transplant recipients (kidney, heart, kidney-pancreas); Treatment of CMV retinitis in patients with AIDS; Reduction of CMV viral load and end-organ disease. NutriStack rates the overall evidence as strong.
What is a typical dose of Valganciclovir?
A typical adult dose of Valganciclovir is CMV retinitis induction: 900 mg twice daily with food for 21 days, then 900 mg once daily maintenance. Transplant prophylaxis: 900 mg once daily with food, started within 10 days of transplant and continued for ~100-200 days depending on organ and risk. All doses require reduction for reduced creatinine clearance.. The commonly recommended form is Oral tablet (450 mg) or oral solution (50 mg/mL); take with food to improve bioavailability.. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Valganciclovir?
Reported side effects include neutropenia and leukopenia, anemia, thrombocytopenia, diarrhea, nausea, and vomiting, headache, fever. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Valganciclovir?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Valganciclovir in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.